Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NVCR

+ Watchlist+ Portfolio

NovoCure Limited

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$11.14
52-Week Range
$9.82 – $21.45
Market Cap
$1.25B
P/E (TTM)
—
EPS (TTM)
-1.06
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.44
PEG Ratio
—
Return on Equity
-35.19%
Return on Assets
-6.79%
Gross Margin
77.25%
Operating Margin
-16.41%
Profit Margin
-16.78%
Current Ratio
2.49
Debt/Equity
0.66
Total Debt
$231.55M
Free Cash Flow
$9.00M
Revenue Growth
15.70%
Earnings Growth
—
Enterprise Value
$1.02B

Market Snapshot

About

NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) therapy, a novel cancer treatment that uses electric fields to disrupt cell division in tumors. The flagship product Optune is FDA-approved for glioblastoma and mesothelioma. NovoCure is conducting clinical trials across multiple solid tumor types including brain, lung, ovarian, and pancreatic cancers.